ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the company's schedule of key news announcements and events during the Transcatheter Cardiovascular Therapeutics (TCT) 2009 conference in San Francisco, Sept. 21 - 25. Highlights include the presentation of new scientific data on the company's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. One-year results from the SPIRIT IV trial, which will be presented as a late-breaking clinical trial on Wednesday, Sept. 23, will provide valuable information about the efficacy and safety of XIENCE V compared to Boston Scientific's TAXUS(R) Paclitaxel-Eluting Coronary Stent System. In addition, three-year results from the SPIRIT III trial will provide insights about the long-term safety and efficacy of XIENCE V.
"As part of our continued leadership in advancing the treatment of vascular disease and improving patient care, we look forward to the presentations of SPIRIT III and SPIRIT IV data, which promise to provide important insights about the performance and safety of our market-leading XIENCE V drug eluting stent," said Robert Hance, senior vice president, vascular, Abbott. "With our vascular division headquarters and thousands of company employees in the Bay Area, Abbott is looking forward to welcoming the TCT conference and physicians from around the world to San Francisco."
Key presentations and events are as follows (all times are Pacific; all events are at the Moscone Center unless otherwise noted):
Monday, Sept. 21:
- SPIRIT III: Three-year results from SPIRIT III, a large-scale pivotal clinical trial comparing XIENCE V to TAXUS in 1,002 patients, will be presented by Gregg W. Stone, M.D., of Columbia University Medical Center and principal investigator of the SPIRIT III trial, during the Drug-Eluting Stent (DES) Summit at 5:43 p.m. in Room 104.
Tuesday, Sept. 22:
- ABSORB: During the DES Summit in Room 104, John A. Ormiston, M.D., of Mercy Hospital, New Zealand, and Patrick W. Serruys, M.D., Ph.D., of Thoraxcentre, Erasmus University Hospital, the Netherlands, will discuss two-year data from the first stage of Abbott's ABSORB trial, the world's first trial to study a fully bioabsorbable drug eluting device for coronary artery disease. Dr. Ormiston will provide a clinical overview at 4:21 p.m., and Professor Serruys will review serial angiography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging results at 4:31 p.m.
Wednesday, Sept. 23:
- The Fourth Revolution: At the "Fully Bioabsorbable Devices" breakfast symposium from 6:30 a.m. to 8 a.m. in Room 124, Abbott will provide an update on the company's bioabsorbable device program being studied outside the United States. Speakers include Dr. Ormiston; Professor Serruys; Ian T. Meredith, MBBS, Ph.D., of Monash Medical Centre, Australia; and Renu Virmani, M.D., of CVPath Institute.
- SPIRIT IV: One-year results from the SPIRIT IV study will be presented by Dr. Stone during the first late-breaking clinical trials session of the TCT conference at 11 a.m. in the Esplanade Ballroom. SPIRIT IV is the largest randomized clinical trial ever presented between two drug eluting stents, with 3,690 patients - including more than 1,000 patients with diabetes. Dr. Stone is the principal investigator of the SPIRIT IV trial.
- TCT Investor Meeting: Abbott will host an investor meeting from 12:45 p.m. to 2 p.m. to review the one-year results from SPIRIT IV and provide an overview of the company's vascular business and pipeline. The live Web cast of the meeting will be available from Abbott's Investor Relations Web site at www.abbottinvestor.com.
- The SPIRIT of Leadership: During the "New DES Results and Future Innovations" evening symposium from 7 p.m. to 10 p.m. at the Hilton San Francisco, Grand Ballroom, Dr. Stone will discuss the SPIRIT IV results and David Cox, M.D., of Lehigh Valley Hospital, will discuss the SPIRIT III results. In addition, John A. McPherson, M.D., of Vanderbilt Heart and Vascular Institute, will present data from XIENCE EXCEED, a post-approval study evaluating the stent's acute performance, deliverability and resource utilization in the catheterization lab. The symposium will be moderated by Ron Waksman, M.D., of the Washington Hospital Center.
Thursday, Sept. 24:
- Vessel Closure: During the "Modern Approaches to Vascular Access Management" breakfast symposium from 6:30 a.m. to 8 a.m. in Room 123, experts will review the latest clinical information for improving patient care and driving hospital efficiency through the use of vascular closure devices and discuss the future of closure devices. Speakers include David Lee, M.D., of Stanford University Medical Center; Thomas Stuver, M.D., of Rochester General Hospital; Ramin Ebrahimi, M.D., of UCLA Medical Center and Greater Los Angeles VA Medical Center; and William Jordan Jr., M.D., of University of Alabama at Birmingham Hospital.
- PROSPECT: Findings from Abbott's PROSPECT trial will be presented by Dr. Stone at 12:15 p.m. during the late-breaking trials session in the Esplanade Ballroom. PROSPECT is a first-of-its-kind natural history study designed to help advance scientific understanding around vulnerable plaque and its possible role in causing heart attacks. Approximately 700 patients with acute coronary syndrome were enrolled into the study at centers in the United States and Europe.
Throughout the week, Abbott will showcase its latest products at booth #1316 in the exhibit hall. The booth also will feature Abbott's vascular pipeline, as well as resources and programs for physicians and patients, such as Abbott's new Women's Heart Health Initiative.
About XIENCE V
Abbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.
Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.
XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Related medicine news :1
. Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts2
. Abbott Again Named One of the Best Places to Launch a Career by BusinessWeek3
. Abbott to Acquire Visiogen, Expanding Vision Care Portfolio4
. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference5
. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets6
. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy7
. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent8
. Abbott Testifies Before U.S. Congress on Role of Private Sector in Advancing Science Education9
. Abbott to Acquire Nutrition Businesses, Expanding Presence in India10
. Abbott and Medtronic Reach Agreement on Global Patent Disputes11
. NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test